Epitalon

Overview

Epitalon — also spelled Epithalon and known by the sequence shorthand AEDG — is a short synthetic tetrapeptide composed of L-alanine, L-glutamic acid, L-aspartic acid and glycine. It was rationally designed in the late 1980s by the team of Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology, as a synthetic equivalent of the active fraction of epithalamin, a polypeptide extract of bovine pineal gland.

In the original Russian research programme, short peptides isolated from pineal, thymic and other tissues were proposed as 'cytomedines' — endogenous regulators capable of influencing tissue-specific gene expression. Epitalon emerged as the most-studied member of this family, and its proposed mechanisms span telomerase activation, melatonin rhythm restoration and modulation of neuroendocrine ageing markers.

Outside of the post-Soviet literature Epitalon remains a niche subject, but interest from the international longevity research community has grown in parallel with broader investigation of telomerase modulation as an anti-ageing target. This page summarises the published preclinical and limited human pilot data, the proposed mechanisms of action, the safety profile reported in those studies, and the regulatory framing in the United Kingdom.

Nothing on this page is medical advice. Epitalon is not a licensed medicine in the UK, the EU or the United States, and the data summarised here is provided for laboratory and research use only.

Mechanism of action

The primary mechanism most often attributed to Epitalon is induction of telomerase activity. In a 2003 in vitro experiment by Khavinson and colleagues, addition of micromolar concentrations of the peptide to cultured human somatic fibroblasts produced a measurable increase in telomerase reverse transcriptase activity and a corresponding extension of telomere length across 10–20 passages, with cell cultures continuing to divide beyond the Hayflick limit observed in untreated controls. The authors proposed that AEDG binds short stretches of DNA in promoter regions of telomerase-associated genes, increasing transcription of hTERT.

A second strand of research focuses on the pineal axis. Rodent studies repeatedly report that Epitalon administration normalises age-related declines in nocturnal melatonin secretion and restores entrainment of circadian rhythms in old animals. The proposed pathway is restoration of pinealocyte function — either by direct gene-regulatory effects on serotonin-N-acetyltransferase (AANAT) and related enzymes, or indirectly by reducing neuroendocrine stress signalling.

Beyond telomerase and pineal effects, Epitalon has been examined for effects on glucose tolerance, immune competence, lipid peroxidation markers and reproductive-axis hormones in aged rodents. Across these end-points the reported pattern is consistent: aged animals treated with the peptide trend toward biomarker profiles characteristic of younger animals, although effect sizes are typically modest and methods of measurement vary across publications.

Mechanistically the peptide is hypothesised to act as a 'gene-regulatory short peptide': because of its small size it is proposed to reach the nucleus intact and to bind DNA at specific motifs. This model is plausible but has not been fully resolved by independent crystallographic or chromatin-immunoprecipitation work outside the original group, and remains the most actively debated aspect of Epitalon pharmacology.

Research history

Epitalon was first synthesised in the late 1980s as part of the cytomedine programme led by Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology (founded 1992). The compound was registered in Russia as a research peptide and was the subject of an extensive in-house programme through the 1990s and 2000s.

The most-cited animal work is a series of long-term experiments in CBA mice and Wistar rats reporting that pulsed administration of Epitalon increased mean and maximum lifespan, reduced the incidence of spontaneous tumour formation, and preserved oestrous cyclicity in females past the age at which controls became acyclic. A widely cited 2003 paper by Anisimov and Khavinson reported a ~12% increase in mean lifespan in female CBA mice receiving Epitalon over multiple courses.

Limited human work has also been published, predominantly in Russian-language gerontology journals. A multi-year open-label observational study in elderly patients reported improvements in self-reported sleep quality and physical performance scores, although study designs lacked blinding and modern placebo control. No large randomised controlled trial of Epitalon in humans has been registered with EU or US regulators.

Summarised studies